1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Alexza Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Alexza Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 62 pages

Alexza Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Alexza Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Alexza Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alexza Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Alexza Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alexza Pharmaceuticals, Inc. - Brief Alexza Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alexza Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alexza Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alexza Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alexza Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alexza Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alexza Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alexza Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alexza Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Alexza Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Alexza Pharmaceuticals, Inc. Snapshot 5
Alexza Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Alexza Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Alexza Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Alexza Pharmaceuticals, Inc. - Pipeline Products Glance 10
Alexza Pharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Alexza Pharmaceuticals, Inc. - Drug Profiles 11
alprazolam 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Alexza Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 13
Alexza Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 14
Alexza Pharmaceuticals, Inc. - Recent Pipeline Updates 15
Alexza Pharmaceuticals, Inc. - Dormant Projects 16
Alexza Pharmaceuticals, Inc. - Company Statement 17
Alexza Pharmaceuticals, Inc. - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Alexza Pharmaceuticals, Inc., Recent Developments 23
Alexza Pharmaceuticals, Inc.- Press Release 23
Feb 21, 2013: Alexza Pharma And Ferrer Internacional Announce European Marketing Authorization For Adasuve 23
Dec 07, 2010: Alexza Pharmaceuticals Provides Regulatory Update For AZ-004 24
Oct 11, 2010: Alexza Receives Complete Response Letter For AZ-004 NDA 24
Jul 12, 2010: Alexza Updates Staccato Pipeline And Outlines Pipeline Development Strategy 25
May 26, 2010: Alexza Presents Additional Phase III Analyses and Phase I Cardiovascular Safety Data Of Staccato Loxapine 26
Feb 11, 2010: Alexza Announces AZ-004 PDUFA Goal Date Of October 11, 2010 27
Feb 10, 2010: Alexza And Biovail Collaborate To Develop And Commercialize AZ-004 (Staccato Loxapine) In North America 27
Financial Deals Landscape 29
Alexza Pharmaceuticals, Inc., Deals Summary 29
Alexza Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 31
Partnerships 31
Alexza Pharma Enters Into Licensing Agreement With Endo Pharma 31
Alexza Pharma Enters Into Co-Marketing Agreement With Grupo Ferrer International For Adasuve 33
Licensing Agreements 35
Cypress Bioscience Enters Into Licensing Agreement With Alexza Pharma 35
Alexza Pharma Enters Into Licensing Agreement With Biovail Labs 37
Equity Offering 39
Alexza Pharma Completes Private Placement Of Shares For $5.5 Million 39
Alexza Pharma Completes Private Placement Of Shares For $3 Million 42
Alexza Pharma Completes Public Offering Of Common Stock For $22 Million 44
Alexza Pharma Completes Private Placement Of Units For $16 Million 46
Alexza Pharma Completes Registered Direct Offering Of $18 Million 48
Alexza Pharma Announces Private Placement Of $25 Million 50
Alexza Pharma Completes Private Placement Of $1 Million 52
Alexza Pharma Completes Private Placement Of $19.7 Million 53
Alexza Pharma Completes Private Placement Of $10 Million 55
Alexza Pharma Completes Public Offering Of $70.73 Million 57
Acquisition 59
Alexza Pharma Acquires Symphony Allegro From Symphony Capital 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62



List of Tables

Alexza Pharmaceuticals, Inc., Key Information 5
Alexza Pharmaceuticals, Inc., Key Facts 5
Alexza Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Alexza Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Alexza Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Alexza Pharmaceuticals, Inc. - Phase II, 2013 10
Alexza Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 13
Alexza Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 14
Alexza Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 15
Alexza Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 16
Alexza Pharmaceuticals, Inc., Subsidiaries 22
Alexza Pharmaceuticals, Inc., Deals Summary 29
Alexza Pharma Enters Into Licensing Agreement With Endo Pharma 31
Alexza Pharma Enters Into Co-Marketing Agreement With Grupo Ferrer International For Adasuve 33
Cypress Bioscience Enters Into Licensing Agreement With Alexza Pharma 35
Alexza Pharma Enters Into Licensing Agreement With Biovail Labs 37
Alexza Pharma Completes Private Placement Of Shares For $5.5 Million 39
Alexza Pharma Completes Private Placement Of Shares For $3 Million 42
Alexza Pharma Completes Public Offering Of Common Stock For $22 Million 44
Alexza Pharma Completes Private Placement Of Units For $16 Million 46
Alexza Pharma Completes Registered Direct Offering Of $18 Million 48
Alexza Pharma Announces Private Placement Of $25 Million 50
Alexza Pharma Completes Private Placement Of $1 Million 52
Alexza Pharma Completes Private Placement Of $19.7 Million 53
Alexza Pharma Completes Private Placement Of $10 Million 55
Alexza Pharma Completes Public Offering Of $70.73 Million 57
Alexza Pharma Acquires Symphony Allegro From Symphony Capital 59



List of Figures

Alexza Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Alexza Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Alexza Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.